KEYTRUDA® (pembrolizumab) KEYNOTE-048 clinical data presentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Click here to download KEYNOTE-048 clinical data presentation

PDF, 2.70 MB

Download this slide deck for information on KEYNOTE-048.

More information about KEYTRUDA® (pembrolizumab) in first-line head and neck squamous cell carcinoma:

Visit product page

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-OHN-00420 | Date of Preparation: August 2022